DiaMedica Therapeutics Inc (DMAC) NPV

Sell:$3.52Buy:$4.00$0.06 (1.71%)

Prices delayed by at least 15 minutes
Sell:$3.52
Buy:$4.00
Change:$0.06 (1.71%)
Prices delayed by at least 15 minutes
Sell:$3.52
Buy:$4.00
Change:$0.06 (1.71%)
Prices delayed by at least 15 minutes

Company Information

About this company

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Key people

Rick Pauls
President, Chief Executive Officer, Director
Scott Kellen
Chief Financial Officer, Company Secretary
Ambarish Shah
Chief Technology Officer
Dominic Cundari
Chief Commercial Officer
Lorianne K. Masuoka
Chief Medical Officer
David J. Wambeke
Chief Business Officer
Daniel J. O'Connor
Director
Michael Giuffre
Independent Director
Richard E. Kuntz
Independent Director
Tanya N. Lewis
Independent Director
James T. Parsons
Independent Director
Click to see more

Key facts

  • EPIC
    DMAC
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA25253X2077
  • Market cap
    $150.52m
  • Employees
    27
  • Shares in issue
    42.88m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.